Clinical Significance of Additional Cytogenetic Abnormalities (ACA) at Disease Progression in Patients with High-Risk Myelodysplastic Syndrome (MDS) Treated with Azacitidine

被引：0
|
作者：
Naito, Chiaki [1 ]
Shimizu, Hiroaki [2 ]
Miyazawa, Yuri [3 ]
Ishizaki, Takuma [4 ]
Yokohama, Akihiko [5 ]
Saito, Takayuki [6 ]
Tsukamoto, Norifumi [7 ]
Handa, Hiroshi [8 ]
机构：
[1] Gunma Univ Hosp, Dept Hematol, Maebashi, Gumma, Japan
[2] Gunma Univ, Dept Hematol, Grad Sch Med, Maebashi, Gunma, Japan
[3] Gunma Univ Hosp, Dept Hematol, Masbashi, Gunma, Japan
[4] Gunma Univ Hosp, Dept Hematol, Maebashi, Gumma, Japan
[5] Gunma Univ Hosp, Blood Transfus Serv, Maebashi, Gumma, Japan
[6] Gunma Univ, Grad Sch Hlth Sci, Maebashi, Gumma, Japan
[7] Gunma Univ Hosp, Ctr Oncol, Maebashi, Gumma, Japan
[8] Gunma Univ, Dept Hematol, Grad Sch Med, Maebashi, Gumma, Japan
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-127956
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5434
引用
收藏
页数：3
相关论文
共 50 条
  • [21] MONITORING OF THE CYTOGENETIC ALTERATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA/MYELODYSPLASTIC SYNDROME TREATED WITH AZACITIDINE
    De Gusmao, B.
    Campeny, A.
    Perez-Persona, E.
    Oiartzabal, I.
    Ardanaz, M.
    Menchaca, M.
    Mendizabal, A.
    Wong, J.
    Pereda, A.
    de Castro, J.
    HAEMATOLOGICA, 2013, 98 : 582 - 583
  • [22] Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure
    Harel, Stephanie
    Cherait, Amina
    Berthon, Celine
    Willekens, Christophe
    Park, Sophie
    Rigal, Marthe
    Brechignac, Sabine
    Thepot, Sylvain
    Quesnel, Bruno
    Gardin, Claude
    Ades, Lionel
    Fenaux, Pierre
    Braun, Thorsten
    LEUKEMIA RESEARCH, 2015, 39 (05) : 501 - 504
  • [23] Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
    Prebet, Thomas
    Gore, Steven D.
    Esterni, Benjamin
    Gardin, Claude
    Itzykson, Raphael
    Thepot, Sylvain
    Dreyfus, Francois
    Rauzy, Odile Beyne
    Recher, Christian
    Ades, Lionel
    Quesnel, Bruno
    Beach, C. L.
    Fenaux, Pierre
    Vey, Norbert
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) : 3322 - 3327
  • [24] IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE
    Improta, S.
    Della Cioppa, P.
    Esposito, M.
    Gagliardi, A.
    Lucania, A.
    Izzo, G. Nitrato
    Villa, M. R.
    Mastrullo, L.
    LEUKEMIA RESEARCH, 2015, 39 : S52 - S53
  • [25] IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE
    Villa, M. R.
    Gagliardi, A.
    Della Cioppa, P.
    Esposito, M.
    Lucania, A.
    Izzo, G. Nitrato
    Improta, S.
    Mastrullo, L.
    HAEMATOLOGICA, 2016, 101 : S120 - S121
  • [26] Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine
    Laribi, Kamel
    Bolle, Delphine
    Alani, Mustafa
    Ghnaya, Habib
    Besancon, Anne
    Farhi, Jonathan
    Mheidly, Kayane
    Denizon, Nathalie
    de Materre, Alix Baugier
    CANCER MEDICINE, 2019, 8 (05): : 2188 - 2195
  • [27] IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE
    Improta, S.
    Della Cioppa, P.
    Lucania, A.
    Esposito, M.
    Mastrullo, L.
    HAEMATOLOGICA, 2015, 100 : 103 - 104
  • [28] IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE
    Improta, S.
    Villa, M. R.
    Della Cioppa, P.
    Lucania, A.
    Esposito, M.
    Izzo, G. Nitrato
    Gagliardi, A.
    Mastrullo, L.
    HAEMATOLOGICA, 2017, 102 : 766 - 767
  • [29] Clonal evolution in high-risk MDS and secondary AML treated with venetoclax and azacitidine
    Koch, R.
    Ganster, C.
    Dierks, S.
    Shirneshan, K.
    Rittscher, K.
    Nothnick, G.
    Becker, S.
    Shumilov, E.
    Haase, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 199 - 199
  • [30] To bleed or not to bleed: Identifying the clinical significance of platelet function abnormalities in myelodysplastic syndrome (MDS)
    Sellors, A.
    Gooding, R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 133 - 134
12345